Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
Total Valuation
Pyxis Oncology has a market cap or net worth of $81.77M. The enterprise value is $67.01M.
Market Cap$81.77M
Enterprise Value$67.01M
Share Statistics
Pyxis Oncology has 61,947,666 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,947,666
Owned by Insiders10.31%
Owned by Institutions25.01%
Financial Efficiency
Pyxis Oncology’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -62.38%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-62.38%
Return on Capital Employed (ROCE)-0.64
Revenue Per Employee366.95K
Profits Per Employee-1.76M
Employee Count44
Asset Turnover0.10
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pyxis Oncology is -1.18. Pyxis Oncology’s PEG ratio is ―.
PE Ratio-1.18
PS Ratio0.00
PB Ratio0.54
Price to Fair Value0.76
Price to FCF-1.15
Price to Operating Cash Flow-1.13
PEG Ratio―
Income Statement
In the last 12 months, Pyxis Oncology had revenue of 16.15M and earned -77.33M in profits. Earnings per share was -1.32.
Revenue16.15M
Gross Profit15.67M
Operating Income-89.46M
Pretax Income-79.50M
Net Income-77.33M
EBITDA-65.51M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -57.61M and capital expenditures -237.00K, giving a free cash flow of -57.85M billion.
Operating Cash Flow-57.61M
Free Cash Flow-57.85M
Free Cash Flow per Share-0.93
Dividends & Yields
Pyxis Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change-67.37%
50-Day Moving Average1.09
200-Day Moving Average2.12
Relative Strength Index (RSI)54.78
Average Volume (3m)427.30K
Important Dates
Pyxis Oncology upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Pyxis Oncology as a current ratio of 7.49, with Debt / Equity ratio of 16.73%
Current Ratio7.49
Quick Ratio7.49
Debt to Market Cap0.00
Net Debt to EBITDA-0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Pyxis Oncology has paid -2.16M in taxes.
Income Tax-2.16M
Effective Tax Rate0.03
Enterprise Valuation
Pyxis Oncology EV to EBITDA ratio is -1.40, with an EV/FCF ratio of -1.59.
EV to Sales5.69
EV to EBITDA-1.40
EV to Free Cash Flow-1.59
EV to Operating Cash Flow-1.59
Balance Sheet
Pyxis Oncology has $126.93M in cash and marketable securities with $20.20M in debt, giving a net cash position of -$106.73M billion.
Cash & Marketable Securities$126.93M
Total Debt$20.20M
Net Cash-$106.73M
Net Cash Per Share-$1.72
Tangible Book Value Per Share$2.02
Margins
Gross margin is 86.52%, with operating margin of -554.07%, and net profit margin of -478.95%.
Gross Margin86.52%
Operating Margin-554.07%
Pretax Margin-492.35%
Net Profit Margin-478.95%
EBITDA Margin-405.76%
EBIT Margin-424.23%
Analyst Forecast
The average price target for Pyxis Oncology is $6.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.83
Price Target Upside450.81% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast30.51%